期刊文献+

进口与国产卡培他滨在结直肠癌化疗CapeOx方案中的有效性和安全性比较

下载PDF
导出
摘要 目的观察比较结直肠癌化疗CapeOx方案中进口卡培他滨与国产卡培他滨的用药效果。方法选择医院收治的晚期结直肠癌患者78例,均采用CapeOx化疗方案治疗,根据患者个人意愿将其分为A、B组,每组39例。A组应用进口卡培他滨治疗,B组则选用国产卡培他滨治疗,比较2组治疗效果、不良反应发生率及治疗费用。结果 A组总有效率为41. 18%,高于B组的18. 18%(P <0. 05); 2组均未发生Ⅳ级毒性反应,2组间不良反应发生率比较差异无统计学意义(P> 0. 05);随访1年,2组无进展生存期比较差异无统计学意义(P> 0. 05); A组卡培他滨的治疗费用为(895. 20±6. 58)元,高于B组的(381. 09±6. 27)元(P <0. 01)。结论在结直肠癌CapeOx化疗方案中使用进口卡培他滨的临床疗效优于国产卡培他滨,但国产卡培他滨的治疗费用远低于进口卡培他滨,且两者相关药物不良反应发生率无显著性差异,因此临床医师可根据患者的经济状况及其个人意愿合理选择药物。
作者 李德华
出处 《临床合理用药杂志》 2018年第29期54-55,共2页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献4

二级参考文献37

  • 1Georgios V Koukourakis,Georgios Zacharias,John Tsalafoutas,Dimitrios Theodoridis,Vassilios Kouloulias.Capecitabine for locally advanced and metastatic colorectal cancer:A review[J].World Journal of Gastrointestinal Oncology,2010,2(8):311-321. 被引量:4
  • 2季加孚.胃癌外科的现状与发展趋势[J].中国普外基础与临床杂志,2006,13(1):1-3. 被引量:65
  • 3Vincenzi B,Frezza AM,Schiavon G. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox Ⅳ[J].{H}SUPPORTIVE CARE IN CANCER,2013,(05):1313-1319.
  • 4Georgiou PA,Tekkis PP,Constantinides VA. Diagnostic accuracy and value of magnetic resonance imaging (MRI) in planning exenterative pelvic surgery for advanced colorectal cancer[J].{H}EUROPEAN JOURNAL OF CANCER,2013,(01):72-81.
  • 5Mirakhorli M,Rahman SA,Abdullah S. Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy[J].Mol Med Rep,2013,(02):613-617.
  • 6Ng SC,Lau JY,Chan FK. Increased risk of advanced neoplasms among asymptomatic siblings of patients with colorectal cancer[J].{H}GASTROENTEROLOGY,2013,(03):544-550.
  • 7Landry JC,Feng Y,Cohen SJ. Phase 2 study of preoperative radiation with concurrent capecitabine,oxaliplatin,and bevacizumab followed by surgery and postoperative 5-fluorouracil,leucovorin,oxaliplatin (FOLFOX),and bevacizumab in patients with locally advanced rectal cancer:ECOG 3204[J].{H}CANCER,2013,(08):1521-1527.
  • 8Vincenzi B,Zoccoli A,Schiavon G. Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients[J].{H}EUROPEAN JOURNAL OF CANCER,2013,(06):1501-1508.
  • 9Infante JR,Bendell JC,Goff LW. Safety,pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody,KRN330,in patients with advanced colorectal cancer[J].{H}EUROPEAN JOURNAL OF CANCER,2013,(06):1169-1175.
  • 10Yeh YS,Tsai HL,Ma CJ. A retrospective study of the safety and efficacy of a first-line treatment with modified FOLFOX-4 in unresectable advanced or recurrent gastric cancer patients[J].{H}CHEMOTHERAPY,2012,(05):411-418.

共引文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部